is glp-1 a scam weight-loss drops marketed to Australians contain 'basically salty water', analysis finds | Scams BBB receiving numerous complaints over

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Theres no evidence that they have any sort of substantially lingering effect once you stop taking them, said Patrick ONeil, Ph.D., director of the MUSC Weight Management Center and a professor in the Department of Psychiatry and Behavioral Sciences

The Truth About GLP-1s, provided an overview of GLP-1s and their role in the current weight-management industry

People are wanting guidance on where to begin and support to help them make changes they can actually sustain

As GLP1 use rises, new patient volume for hypertension and cholesterol therapies has declined, while GERD treatments remain stable due to GLP1s mixed impact, showing ripple effects across multiple disease areas

With GLP-1 adoption accelerating, size is changing, but so is identity